Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718632 | 0.94 | MCHR1 (0.47) | CCR3HTR2AHTR2CMCHR1MET | |
| SCHEMBL4717402 | 0.92 | MCHR1 (0.51) | CCR3HTR2AHRH3MCHR1MET | |
| SCHEMBL4717448 | 0.87 | EPHX2 (0.46) | CCR3HTR2AHTR2CHRH3KCNH2 | |
| SCHEMBL4714395 | 0.85 | HRH3 (0.45) | CCR3HTR2AHRH3MCHR1KDR | |
| SCHEMBL4715395 | 0.85 | MCHR1 (0.52) | MCHR1MCHR2 | |
| SCHEMBL4716640 | 0.85 | MCHR1 (0.44) | CCR3HTR2CHRH3MCHR1MCHR2 | |
| SCHEMBL4718602 | 0.85 | ALDH1A1 (0.46) | MCHR1MCHR2KDRFLT1FLT4 | |
| SCHEMBL4717277 | 0.85 | MAPK1 (0.47) | HTR2AHTR2CHRH3MCHR1 | |
| SCHEMBL4717814 | 0.84 | BRAF (0.46) | HTR2AHTR2CHRH3MCHR1MCHR2 | |
| SCHEMBL4715838 | 0.83 | MAPK14 (0.48) | MCHR1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | CCR3 3102/4885HTR2A 1982/4885HTR2C 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.